22:50 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Asthma...
20:22 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

FDA approves Paratek antibiotics

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Oct. 2 for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure...
23:45 , Oct 2, 2018 |  BC Extra  |  Company News

FDA approves Paratek antibiotics

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Tuesday for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections...
03:20 , Aug 17, 2018 |  BC Week In Review  |  Company News

Almirall acquires U.S. dermatology products from Allergan

Almirall S.A. (Madrid:ALM) will acquire a portfolio of five dermatology products marketed in the U.S. from Allergan plc (NYSE:AGN) for $550 million in cash. The portfolio, which generated 1H18 sales of $70 million, includes acne...
00:20 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Athenex's actinic keratosis ointment meets in pair of Phase III trials

Athenex Inc. (NASDAQ:ATNX) said KX2-391 (KX-01) met the primary endpoint of improving the proportion of patients who achieved complete clearance of actinic keratosis (AK) lesions within the face or scalp treatment areas at day 57...
22:56 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified p53-activating tetrahydroindazole-based DHODH inhibitors that could help treat melanoma. Screening of a small molecule library in human melanoma cell line-based assays of p53-dependent transcription, followed by chemical...
18:29 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Sun's IL-23 psoriasis mab approved by FDA

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya is a humanized mAb against IL-23 subunit...
18:41 , Mar 21, 2018 |  BC Extra  |  Company News

Sun's IL-23 mAb gets FDA approval for psoriasis

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya is a humanized mAb against IL-23 subunit...
18:14 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic lymphocytic leukemia (CLL) Patient sample, cell culture and mouse studies suggest inhibiting IL23P19-IL-23 receptor signaling could help treat CLL. In peripheral blood mononuclear cells (PBMCs) from patients, high levels of IL-23 receptor were...
23:03 , Jan 25, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...